Kymera Q4 revenue misses expectations, net loss widens

Kymera Therapeutics

26/02/2026 12:23

Overview

Biopharmaceutical firm's Q4 revenue missed analyst expectations

Net loss for Q4 widened compared to the previous year

Company ended 2025 with $1.6 bln cash, runway into 2029

Outlook

Kymera expects data from KT-621 Phase 2b trials in mid-2027 and late-2027

Company anticipates KT-579 Phase 1 trial data in second half of 2026

Kymera projects cash runway into 2029 with $1.6 bln in cash

Result Driver

R&D EXPENSES - Increased due to investment in STAT6 program and discovery initiatives

Company press release: ID:nGNXc5PvnQ

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Miss
$2.87 mln
$15.05 mln (20 Analysts)
Q4 EPS
-$0.97
Q4 Net Income
-$86.98 mln
Q4 Operating Expenses
$100.77 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 22 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Kymera Therapeutics Inc is $116.00, about 27.9% above its February 25 closing price of $90.68

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)